Results 171 to 180 of about 2,422,535 (304)
Descriptive statistics of factor scores. (n = 53, FAMERP, 2024, Brazil).
Thales Guardia de Barros (22216025), Emerson Roberto dos Santos (20455194), João Daniel de Souza Menezes (20501001), Matheus Querino da Silva (22216028), Marco Antonio Ribeiro Filho (22216031), Fabio Argollo Ferreira (22216034), Lucas Antonio Moura Gonzalez (22216037), Aparecida Custódio Da Silva (22216040), Izabelle Pereira Trindade (22216043), Luana Mari Takahashi (22216046), Natalia Almeida de Arnaldo Silva Rodrigues Castro (20500998), Loiane Letícia dos Santos (22216049), Camila Borge de Freitas (22216052), Natália Aparecida de Oliveira (22216055), William Donegá Martinez (20501013), Alex Bertolazzo Quitério (20455197), Ana Julia de Deus Silva (22216058), Luiz Otávio Maciel Lopes (22216061), Sônia Maria Maciel Lopes (22216064), Camila Aline Lázaro (22216067), Maria Laura Fabris (22216070), Maysa Alahmar Bianchin (6148523), Gerardo Maria de Araújo Filho (22216073), Denise Cristina Móz (22216076), Vaz Oliani (22216079), Antônio Hélio Oliani (22216082), Neuza Alves Bonifácio (17560690), Aparecida de Fátima Michelin (22216085), Vânia Maria Sabadoto Brienze (20455206), Júlio César André (6209801), Patrícia da Silva Fucuta (20501016) +30 moreopenalex +1 more sourceEffective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet +17 morewiley +1 more sourceExploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
Molecular Oncology, EarlyView.We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair +17 morewiley +1 more sourceMonitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer
Molecular Oncology, EarlyView.Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien +35 morewiley +1 more sourceLINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma
Molecular Oncology, EarlyView.The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico +12 morewiley +1 more source